Biotechs Urged to Prevent Viral Risks That Cost Genzyme Nearly $300 Million
This article was originally published in The Gold Sheet
Executive Summary
Biotechs should bite the bullet and invest in media treatment to avoid viral contamination, experts say. They point to last year's temporary shutdown of Genzyme's Allston Landing, Mass., which has cost the company $293 million in added expenses and lost revenues so far, and may have reduced the market for its top product by as much as 20 percent. Genzyme looks to add treatment now, but many others still take their chances. What happened when a mouse virus snuck into Genentech's plant 15 years ago? Genentech added high temperature short time heat sterilization treatment and never caught another virus. How Biomarin expanded on Genentech's approach with added layers of protection, including the use of disposable technology. Tips on how to add heat treatment of media for a commercial product.
You may also be interested in...
ICH Revises Viral Safety Guideline For New Types Of Products, Processes And Methods
Draft rewrite issued for comment updates 20-year-old Q5A document with advice around new developments like the advent of viral vectors, continuous manufacturing and next-generation sequencing.
WHO Proposes Reference Standard For Adventitious Virus Detection
Emerging global standard could speed testing of biologics and gene therapies for stray viral particles, while sparing laboratory animals.
Pharma Pursues Generic Injectables Quality Turnaround Opportunities
Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?